Protein Nanospheres for Treating Chemotherapy Dysfunction

ChangeBridge: Patent Apps - Pharma (A61K)

Detected March 26th, 2026

Summary

The USPTO has published a patent application (US20260083683A1) for protein nanospheres designed to treat dysfunction caused by chemotherapy and immunosuppressive therapy. The application details the manufacture and use of fibrinogen-coated albumin spheres (FAS) and High-Fibrinogen Spheres (HFS) for mitigating toxic effects of cancer treatments.

View original document View source feed page

What changed

This document is a USPTO patent application (US20260083683A1) detailing novel protein nanospheres, specifically fibrinogen-coated albumin spheres (FAS) and High-Fibrinogen Spheres (HFS). These nanoparticles are intended to mitigate the toxic effects of chemotherapy, radiological agents, and immunosuppressive therapies used in cancer and autoimmune disease treatments. The application outlines their manufacture and potential mechanisms of action related to immune system balance.

As this is a patent application, it does not impose immediate regulatory obligations or compliance deadlines on regulated entities. However, it signifies potential future developments in pharmaceutical treatments. Companies involved in drug development, particularly in oncology and immunology, should be aware of this technological advancement for potential licensing, partnership, or competitive analysis.

Source document (simplified)

← USPTO Patent Applications

PROTEIN NANOSPHERES AND METHOD TO TREAT DYSFUNCTION FROM CHEMOTHERAPY AND IMMUNOSUPPRESSIVE THERAPY

Application US20260083683A1 Kind: A1 Mar 26, 2026

Inventors

Richard C.K. Yen

Abstract

A protein nanospheres and method to treat dysfunction from chemotherapy and immunosuppressive therapy, and a manufacture of fibrinogen-coated albumin spheres (FAS) and High-Fibrinogen Spheres (HFS) which have higher concentrations of fibrinogen molecules per sphere than FAS, and their use for medical treatments. Both kinds of nanoparticles are effective in the mitigation of the toxic effects of certain chemotherapeutic and radiological agents that are typically used in the treatment of cancer, or the treatment of autoimmune diseases, or for patients with both diseases. FAS and HFS can exert their beneficial effects via a variety of mechanisms which match the need of the body for specific cell types, including any of the subgroups of T cells and antibody producing cells, the relative concentration of each kind is vital to the balance between tumor surveillance and autoimmune disease suppression.